S-1/A: Scorpius Holdings Seeks to Raise Capital Through Public Offering of Common Stock and Pre-Funded Warrants

Scorpius Holdings is conducting a public offering of up to 26,315,789 shares of common stock and pre-funded warrants to raise capital for working capital and general corporate purposes.

Summary

• Scorpius Holdings is offering up to 26,315,789 shares of common stock and pre-funded warrants, with the number of shares decreasing on a one-for-one basis for each pre-funded warrant sold.
• The offering is based on an assumed public offering price of $0.38 per share, which was the last reported sale price on January 16, 2025.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits of 4.99% or 9.99% of the outstanding common stock.
• Each pre-funded warrant is immediately exercisable for one share of common stock at an exercise price of $0.0002 per share.
• The company has granted underwriters a 45-day option to purchase up to 3,947,368 additional shares or pre-funded warrants to cover over-allotments.
• Net proceeds from the offering are estimated to be approximately $6.3 million, or $7.3 million if the over-allotment option is fully exercised, assuming $2.5 million is used to repay a portion of the Secured Convertible Notes.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• The company's common stock is listed on NYSE American under the symbol SCPX.

Sentiment

Score: 4

Explanation: The document highlights the company's need for capital and the risks associated with its financial situation, which is concerning. However, the offering provides a potential source of funding, which is a positive. Overall, the sentiment is slightly negative due to the financial risks.

Positives

• The offering provides a potential source of capital to fund working capital and general corporate purposes.
• The pre-funded warrants offer flexibility for investors who may be subject to ownership limitations.
• The underwriters' over-allotment option could result in additional capital for the company.

Negatives

• The offering may cause the trading price of the common stock to decrease.
• There is no established public trading market for the pre-funded warrants.
• The company has broad discretion in using the net proceeds from the offering.
• The company's cash, together with the proceeds of this offering, is not expected to last beyond April 2025 (or May 2025 if the representative exercises its option to purchase additional shares in full) unless revenue significantly increases.

Risks

• The company has a history of losses and may not be able to achieve profitability.
• The company's ability to continue as a going concern is uncertain.
• The company is dependent on a limited number of customers for a substantial majority of its revenues.
• The company may need additional financing in the future, which may not be available on acceptable terms.
• The company's common stock may be delisted from NYSE American if it fails to meet continued listing requirements.
• The company's management has broad discretion in using the net proceeds from the offering.
• The company may experience dilution of ownership interests due to future issuances of common stock.
• The company's securities may be offered to other investors in other offerings at a price lower than the price per share offered in this Offering, or upon terms which may be deemed more favorable than those offered to investors in this Offering.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes. The company believes the net proceeds of this offering will fund operations through April 2025 (or May 2025 if the representative exercises its option to purchase additional shares in full).

Industry Context

The company operates in the contract development and manufacturing organization (CDMO) sector, providing biologics manufacturing services to the biotechnology and biopharmaceutical industries. This offering is a common method for companies in this sector to raise capital for growth and expansion.

Comparison to Industry Standards

• The offering structure, including the use of pre-funded warrants, is not uncommon for companies with ownership limitations.
• The company's financial situation, including its history of losses and need for additional capital, is not unusual for companies in the early stages of development in the biotechnology and biopharmaceutical industries.
• The company's reliance on a limited number of customers is a risk factor that is common in the CDMO sector, where companies often have a few key clients that account for a significant portion of their revenue.
• The company's need to raise capital through public offerings is a common practice for companies in the biotechnology and biopharmaceutical industries, which often require significant investment in research and development and manufacturing capabilities.

Related Party Transactions

• The company issued a convertible promissory note to Elusys Holdings, Inc., a company controlled by the CEO.
• The company issued a non-convertible promissory note to Elusys Holdings, Inc.
• The company amended the Asset Purchase Agreement with Elusys Holdings, Inc. to eliminate royalty fees in exchange for a cash payment.

Stakeholder Impact

• Shareholders may experience dilution of their ownership interests due to the offering.
• Shareholders may experience a decrease in the trading price of the common stock.
• The offering provides a potential source of capital to fund the company's operations, which could benefit employees and customers.
• The company's ability to continue as a going concern is uncertain, which could impact all stakeholders.

Next Steps

• The company will complete the public offering of common stock and pre-funded warrants.
• The company will use the net proceeds for working capital and general corporate purposes.
• The company will continue to operate its CDMO business and seek to expand its customer base.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, capital raise, biologics manufacturing, CDMO, NYSE American, ThinkEquity, working capital, securities